Kite nails down TCR IP in new licensing pact

Kite Pharma ($KITE) has moved to cement its control of some of the IP behind its work on T cell receptor-based product candidates that zero in on MAGE A3 and A3/A6 antigens. It is paying the NIH an unspecified upfront and milestones in a deal that covers lung, pancreatic, gastric and breast cancers, among others. Kite has long had a very close working relationship with Steven Rosenberg at the NCI. Release

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.